Page last updated: 2024-08-23

fludarabine phosphate and Hematologic Malignancies

fludarabine phosphate has been researched along with Hematologic Malignancies in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bemer, MJ; McCune, JS; O'Donnell, PV; Sandmaier, BM; Sorror, M	1
Chen, J; Hao, Y; Patra, P; Song, S; Yang, X	1
Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL	1
Burnett, A; Dasgupta, RK; Davies, J; Jackson, G; Johnson, P; Morgan, GJ; Poynton, C; Richardson, C; Rule, S; Smith, GM; Stars, AC; Tollerfield, SM; Wareham, E; Wilson, K	1

Trials

3 trial(s) available for fludarabine phosphate and Hematologic Malignancies

Article	Year
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3 Topics: Adult; Aged; Area Under Curve; Biomarkers, Pharmacological; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Transplantation Conditioning; Vidarabine Phosphate; Young Adult	2013
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Busulfan; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Recurrence; Survival Rate; Vidarabine Phosphate	2012
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone marrow transplantation, 2006, Volume: 37, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Melphalan; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate	2006

Other Studies

1 other study(ies) available for fludarabine phosphate and Hematologic Malignancies

Article	Year
Using Gold Nanoparticles as Delivery Vehicles for Targeted Delivery of Chemotherapy Drug Fludarabine Phosphate to Treat Hematological Cancers. Journal of nanoscience and nanotechnology, 2016, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Cell Line, Tumor; Gold; Hematologic Neoplasms; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Spectrophotometry, Ultraviolet; Vidarabine Phosphate	2016

Article

Year

Using Gold Nanoparticles as Delivery Vehicles for Targeted Delivery of Chemotherapy Drug Fludarabine Phosphate to Treat Hematological Cancers.

Journal of nanoscience and nanotechnology, 2016, Volume: 16, Issue:3

Topics: Antineoplastic Agents; Cell Line, Tumor; Gold; Hematologic Neoplasms; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Spectrophotometry, Ultraviolet; Vidarabine Phosphate

2016